NLS Biotech article

Oncopeptides has announced the publication of new real-world data (RWD) that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).

Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product. 

CSL Behring Denmark has announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec).

Anocca has announced the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase I/II multi-asset umbrella trial, VIDAR-1.

All over the Nordics the innovative power is gearing up to put new products, therapies, and preventive measures on the market that will tackle Antimicrobial resistance (AMR) from various angles. 

Norwegian company AdjuTec’s novel antibiotic resistance breakers may help to facilitate reduced use of antibiotics – and the company is now ready to test its product in humans.